CUPERTINO, Calif., June 7 /PRNewswire-FirstCall/ -- In conjunction
with the announcement of a POSIDUR™ (SABER™-Bupivacaine)
collaboration between DURECT Corporation (Nasdaq: DRRX) and
Hospira, Inc. (NYSE: HSP), you are invited to listen to a
conference call that will be broadcast live over the internet on
Monday, June 7, 2010 at 5:00 pm Eastern Time (2:00
pm Pacific Time).
(Logo:
http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)
A live audio webcast of the presentation will be available by
accessing DURECT's homepage at http://www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company
developing innovative drugs for pain and other chronic diseases,
with late-stage development programs including REMOXY®, POSIDUR™,
ELADUR™, and TRANSDUR™-Sufentanil. DURECT's
proprietary oral, transdermal and injectable depot delivery
technologies may enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved
convenience, compliance, efficacy and safety for small molecule and
biologic drugs. For more information, please visit
www.durect.com.
NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are
trademarks of DURECT Corporation. Other referenced trademarks
belong to their respective owners. REMOXY, POSIDUR, ELADUR
and TRANSDUR-Sufentanil are drug candidates under development and
have not been approved for commercialization by the U.S. Food and
Drug Administration or other health authorities.
SOURCE DURECT Corporation